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The renin-angiotensin system (RAS) was extensively investigated and characterized 
throughout the first half of the 20th century. However, its contribution to the mainte-
nance of high blood pressure (BP) in essential hypertension and to the development 
of hypertensive cardiac complications remained under debate until the advent of the 
first pharmacologic probes capable of blocking its actions, namely the angiotensin 
receptor blocker (ARB) saralasin and the angiotensin-converting enzyme inhibitor 
(ACEI) teprotide in the early 1970’s. Using these probes, we could demonstrate that 
even in normal-renin and low-rein hypertension, blockade of the RAS produced a 
fall in BP. And this fall was maximized if the patient had been previously submitted 
to sodium depletion by diuretics or low salt diet, which might produce only a small BP 
fall by itself, but rendered the hypertension RAS-dependent and far more responsible 
to RAS blockade.
In parallel, we had found that excess angiotensin II, either exogenous (in experi-
mental animals) or endogenous, in various clinical settings, could produce significant 
cardiac and renal tissue damage, because the vasculature of these organs is particularly 
sensitive to the constricting effects of angiotensin. In particularly, angiotensin excess 
was shown to produce widespread foci of necrosis and scarring of the myocardium, 
leading to replacement of myocardial tissue by fibrotic tissue, eventually progressing 
to ischemic cardiomyopathy and heart failure.
Treatment of congestive heart failure (CHF) with saralasin or with teprotide 
(both suitable for IV use only, in acute clinical experiments) resulted in significant 
hemodynamic improvements in terms of increased cardiac output, decreased pe-
ripheral arterial resistance, decreased heart rate, increased coronary blood flow and 
diminished myocardial oxygen consumption. These small clinical trials offered the 
“proof of concept” in support of the notion that blockade of the RAS is beneficial 
in the treatment of ischemic cardiomyopathy and heart failure. This concept formed 
the basis for subsequent large randomized long-term outcome trials with oral ACEI’s 
or ARB’s, such as the HOPE, EUROPA, LIFE, CHARM, etc, which have now es-
tablished treatment with an ACEI or ARB as mandatory therapy for patients with 
ischemic heart disease, as well as congestive or chronic heart failure.
It is now universally accepted that initiation of RAS-suppressing therapy with 
an ACEI or ARB in patients with multiple cardiovascular risk factors, not necessary 
including hypertension, offers long-term protection from ischemic heart disease, dia-
stolic and systolic cardiac dysfunction, arrhythmias, as well as protection from renal 
insufficiency, cerebrovascular accidents and new onset type 2 diabetes mellitus.
The molecular events triggered by angiotensin excess and leading to these com-
plications are still poorly understood. We have conducted a number of genomic 
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analyses on tissues of target organs from animals exposed 
to exogenous angiotensin excess using either the microarray 
technique (which reveals changes in expression of selected 
candidate genes placed on the microarray chips), or the serial 
analysis of gene expression (SAGE) technique, which does not 
require a priori knowledge of genes. The former revealed sig-
nificant changes in expression of various genes related to the 
structure and function of cardiomyocytes, including growth 
factors, enzymes, receptors, etc. The latter revealed among 
others, a striking increase in expression of a hitherto unknown 
gene, the cardiomyopathy associated 3 (Cmya 3) gene which we 
were able to sequence and characterize, but whose product(s) 
remain still unknown.
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